Key clinical point: A magnetic resonance imaging (MRI)-based scoring method was sensitive to changes in clinical outcomes of psoriatic arthritis (PsA) caused by abatacept, validating the responsiveness of the OMERACT PsA MRI Scoring System.
Major finding: Until day 169, patients receiving 30 mg/kg abatacept with a switch over to 10 mg/kg and those receiving 10 mg/kg abatacept reported significant reduction in MRI-detected synovitis (−0.97; P = .04) and tenosynovitis (−1.65; P = .01) vs. placebo, with patients switching from placebo to 10 mg/kg abatacept at day 169 showing significant improvements in total inflammation, synovitis, and tenosynovitis ( P < .05) up to day 365.
Study details: This was a post hoc analysis of a phase 2b study including 123 patients with active PsA and an inadequate response to disease-modifying antirheumatic drugs randomly assigned to receive abatacept or placebo.
Disclosures: This study was funded by Bristol Myers Squibb. The authors declared serving on speakers’ bureaus and as consultants or receiving grants/research support from several sources. Six authors declared being employees or shareholders of Bristol Myers Squibb.
Source: Østergaard M et al. Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology (Oxford). 2022 (Feb 8). Doi: 10.1093/rheumatology/keac073